&nbsp;Anaplastic Lymphoma Kinase (ALK) rearrangements lead to the expression of constitutively activated ALK fusion proteins that function as potent oncogenic drivers. Since the discovery of ALK rearrangements in NSCLC, several ALK inhibitors have been developed for the treatment of patients with advanced ALK-rearranged NSCLC.
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Incidence of NSCLC&nbsp;</li>
<li>Total Incident cases of NSCLC patients by Histology</li>
<li>Total Diagnosed cases of NSCLC patients by Stages</li>
<li>Total ALK-NSCLC cases</li>
<li>ALK-NSCLC Treated Patient Pool</li>
</ul>
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Epidemiology&nbsp;
<ul>
<li>The incident cases for ALK-positive mutation in the United States in 2017 were&nbsp;8,449&nbsp;&nbsp;</li>
<li>The United States accounts for around&nbsp;38%&nbsp;of the total patient population of ALK-Positive NSCLC among 7MM</li>
<li>In the case of EU-5, Germany hold up to around&nbsp;29%&nbsp;of the EU-5 Patient population</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0066cc;" href="https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market" target="_blank" rel="noopener noreferrer">Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Market</a>
The total market size of ALK-NSCLC in 7MM&nbsp;in 2017 was&nbsp;USD 841 million&nbsp;
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Market Drivers
<ul>
<li>Increasing Use of Biomarker Testing&nbsp;</li>
<li>Increase in the Mutation Specific Trials Activity and Approval</li>
<li>Increasing Incidence of NSCLC</li>
<li>Label expansion of approved therapies</li>
</ul>
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Market Barriers
<ul>
<li>Cost-Effectiveness of Therapies</li>
<li>Small Patient Populations for Specific Subsets of NSCLC</li>
<li>Generic or Biosimilar Erosion</li>
</ul>
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Emerging Drugs
The Emerging drugs of the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are&nbsp;
<ul>
<li>X-396 (Ensartinib)</li>
</ul>
And many others.&nbsp;
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Marketed Drugs
The Marketed&nbsp;drugs of the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are&nbsp;
<ul>
<li>Lorbrena/Lorviqua (Lorlatinib)&nbsp;</li>
<li>Alunbrig (Brigatinib)</li>
<li>Alecensa (Alectinib)</li>
<li>Xalkori&nbsp;&nbsp;</li>
<li>Zykadia&nbsp;</li>
</ul>
And many others.&nbsp;
&nbsp;
Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) Key Players
The key players in the Anaplastic Lymphoma Kinase-Non Small Cell Lung Cancer (ALK-NSCLC) market are
<ul>
<li>Xcovery</li>
<li>Pfizer</li>
<li>Takeda Pharmaceuticals</li>
<li>Hoffmann-La Roche</li>
<li>Novartis</li>
</ul>
And many others.&nbsp;

ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Market

ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.